Emine Parlak

Emine Parlak

Auto-generated profile, based on publicly available information

Emine Parlak

Atatürk University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2021 in Amino Acids
Verified
Journal Article
Closed access
PDF file
AAAlptug Atila
Alptug Atila
HAHandan Alay
Handan Alay
MYMehmet Emrah Yaman
Mehmet Emrah Yaman
TATugrul Cagri Akman
Tugrul Cagri Akman
ECELIF CADIRCI
ELIF CADIRCI
ZBZafer Bayraktutan
Zafer Bayraktutan

3 November 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
ZKZehra Karacaer
Zehra Karacaer
BCBanu Cakir
Banu Cakir
HEHakan Erdem
Hakan Erdem
KUKenan Ugurlu
Kenan Ugurlu
GDGul Durmus
Gul Durmus
NONecati Ormeci
Necati Ormeci
The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

4 November 2015 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
SŞSeniha Şenbayrak
Seniha Şenbayrak
NONuri Ozkutuk
Nuri Ozkutuk
HEHakan Erdem
Hakan Erdem
IJIsik Somuncu Johansen
Isik Somuncu Johansen
Rok ČivljakRok Čivljak
Rok Čivljak
HVHaluk Vahaboglu
Haluk Vahaboglu
Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any first-line drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38–6.82) and 2.14 (95 % CI, 0:34–13:42), respectively. INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing.

1 March 2015 in Journal of Microbiology and Infectious Diseases
Verified
Journal Article
Open access
EPEmine Parlak
Emine Parlak
AEAYSE ERTURK
AYSE ERTURK
ZKZahide Koşan
Zahide Koşan
MPMehmet Parlak
Mehmet Parlak
ZÖZülal Özkurt
Zülal Özkurt
Objectives: An outbreak of nosocomial Crimean-Congo Hemorrhagic Fever (CCHF) occurred in a university hospital in May 2014. The index case was hospitalized with a preliminary diagnosis of intoxication, liver failure and disseminated intravascular coagulopathy (DIC). The index case, a farmer, died a few hours later with signs of bleeding.\ud Outbreak Investigation: Crimean-Congo Hemorrhagic Fever Polymerase Chain Reaction (PCR) was positive in the index case serum. RT-PCR and/or IgM serology were reported as positive for CCHF virus in all cases.\ud Six health care workers and two relatives in direct or indirect contact with the index case were infected. The main symptoms were myalgia, fatigue, headache, anorexia, sore throat and eruption. Maculopapular rash was observed in five cases. Three patients had exudative tonsillitis. Emergency workers and internal medicine intensive care, radiology and infectious disease personnel had a history of contact with index and/or secondary cases. Ribavirin was given to all patients. One health care worker died because of CCHF.\ud Conclusion: A healthcare worker died due to nosocomial CCHF. This presentation emphasized importance of universal precautions. J Microbiol Infect Dis 2015;5(1): 5-

1 January 2020 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
NINevin Ince
Nevin Ince
SKSafak Kaya
Safak Kaya
İYİlknur Esen Yıldız
İlknur Esen Yıldız
EPEmine Parlak
Emine Parlak
BBBelkıs Bayar
Belkıs Bayar

15 October 2019 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
EAEşref Araç
Eşref Araç
SKSafak Kaya
Safak Kaya
EPEmine Parlak
Emine Parlak
SBSeyit Ali Büyüktuna
Seyit Ali Büyüktuna
ABAli Irfan Baran
Ali Irfan Baran
EGEmrah Günay
Emrah Günay